scholarly journals Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study

2022 ◽  
Vol 11 ◽  
Author(s):  
Yu Liu ◽  
Pingping Li ◽  
Liren Qian
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Salvage Chemotherapy ◽  
T Cell Lymphoma ◽  
High Recurrence Rate ◽  
Term Survival ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
T Cell Lymphomas ◽  
Long Time

Angioimmunoblastic T-cell lymphoma (AITL) is a kind of peripheral T-cell lymphomas (PTCLs) with a highly invasive feature. At present, patients are often treated with CHOP or CHOP-like regimens which is of poor prognosis whilst having high recurrence rate. Once the patient fails to achieve remission or relapse after the first-line treatment, many salvage chemotherapy regimens are always ineffective, and the long-term survival will be difficult to achieve for them. In this circumstance, more effective therapy methods are needed. In this study, two patients with relapsed/refractory AITL were treated with the CAOLD regimen [cyclophosphamide 400 mg/m2 qd d1, cytarabine 30 mg/m2 qd d1–d4, vindesine 2 mg/m2 qd d1, pegaspargase (PEG-ASP) 2,500 IU/m2 qd d2, dexamethasone 7.5 mg/m2 qd d1–d5], and long-term remission was achieved after chemotherapy. One is still alive after achieving complete remission (CR) after two cycles of chemotherapy, who has been followed up for 82 months. Besides, another patient achieved partial remission (PR) after the first course of chemotherapy. Then, CR was obtained after four courses of consolidation chemotherapy. The patient has been followed up for 63 months and is still alive. Both of them achieved long-time survival. These two successful cases demonstrated that the CAOLD regimen can be a better choice for relapsed/refractory AITL and offers hope of breakthrough in this medical field.

scholarly journals Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma

Blood ◽  
2017 ◽  
Vol 129 (9) ◽  
pp. 1095-1102 ◽  
Author(s):  
Matthew A. Lunning ◽  
Julie M. Vose
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Unmet Need ◽  
T Cell Lymphoma ◽  
World Health ◽  
High Dose ◽  
Term Survival ◽  
Angioimmunoblastic T Cell Lymphoma ◽  
The Many

AbstractAngioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature would suggest given the many names that have preceded it. Advanced-stage disease is common with uncharacteristic laboratory and autoimmune findings that often slow or mask the diagnosis. Significant strides in the immunohistochemical and molecular signature of AITL have brought increased ability to diagnose this uncommon type of PTCL. The 2016 World Health Organization classification of lymphoid neoplasms recently acknowledged the complexity of this diagnosis with the addition of other AITL-like subsets. AITL now resides under the umbrella of nodal T-cell lymphomas with follicular T helper phenotype. Induction strategies continue to focus on increasing complete remission rates that allow more transplant-eligible patients to proceed toward consolidative high-dose therapy and autologous stem cell rescue with improving long-term survival. There are several clinical trials in which recently approved drugs with known activity in AITL are paired with induction regimens with the hope of demonstrating long-term progression-free survival over cyclophosphamide, doxorubicin, vincristine, and prednisone. The treatment of relapsed or refractory AITL remains an unmet need. The spectrum of AITL from diagnosis to treatment is reviewed subsequently in a fashion that may one day lead to personalized treatment approaches in a many-faced disease.

Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T-01)

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3566-3566 ◽  
Author(s):  
Thomas Relander ◽  
Grete Fossum Lauritzsen ◽  
Esa Jantunen ◽  
Hans Hagberg ◽  
Harald Anderson ◽  
...  
Keyword(s):  
T Cell ◽  
Induction Chemotherapy ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
T Cell Lymphoma ◽  
Serum Lactate Dehydrogenase ◽  
Term Survival

Abstract Abstract 3566 Primary systemic T-cell lymphoma of anaplastic large cell type (ALCL) is an aggressive and predominantly nodal subtype of lymphoma, further subdivided based on expression of the ALK-protein, with ALK-pos ALCL occurring predominantly in younger patients and associated with a favourable prognosis. ALK-neg ALCL is believed to carry a prognosis similar to that of other nodal peripheral T-cell lymphomas and previous studies have shown long-term survival rates below 50%. There is retrospective data suggesting a benefit from ASCT in first-line treatment of this lymphoma subtype. We analyzed the outcome of ALK-neg ALCL patients included in a prospective phase II trial, NLG-T-01, conducted by the Nordic Lymphoma Group. The NLG T-01 trial enrolled 160 patients aged 18–67 years from the Nordic countries with systemic ALK-neg peripheral T-cell lymphoma within the period 2002–2007. The treatment schedule consisted of 6 courses of CHOEP-14 followed by ASCT (BEAM or BEAC) in responding patients. Patients >60 years received CHOP-14 as induction. Altogether, the trial included 31 patients with ALK-neg ALCL (19% of the study population). Median age was 56 years (22-65) with a male:female ratio of 2.4. Stage III-IV was found in 18 patients (58%), B-symptoms in 19 patients (61%) and 6 patients (19%) had a bulky lesion (>10cm). Pre-therapeutic serum lactate dehydrogenase was elevated in 18 patients (58%) and performance score was 2–4 in 10 patients (32%). After 3 and 6 courses of chemotherapy, response status was CR or CRu in 29% and 58% of the patients, respectively. In total, 24 out of 31 patients (77%) underwent BEAM/BEAC therapy followed by ASCT. Four patients did not respond or had disease progression during induction chemotherapy. The remaining 3 patients did not undergo ASCT for other reasons (mobilization failure, lung insufficiency, patient decision, respectively). Overall response rate after ASCT was 74% for the entire initial population and 96% for those undergoing ASCT. Median follow-up was 45 months. Six patients relapsed after ASCT. There was a total of nine deaths (29%): six due to lymphoma, two due to toxicity and one from second malignancy (colon cancer). With a median follow-up of 45 months, 3-year overall and progression-free survival values were 73% and 64%, respectively. Intensive chemotherapy followed by ASCT was feasible in the majority of the patients included in this prospective trial. Long-term outcome appears promising when compared to previously published data, with the survival curve suggesting a plateau. In ASCT eligible patients, intensive induction chemotherapy consolidated by upfront ASCT is an effective treatment that yields outcome results at least as good as those obtained in age-comparable patients with diffuse large B-cell lymphoma. Disclosures: No relevant conflicts of interest to declare.

scholarly journals Long term survival after treatment of disseminated T cell lymphoma presenting with tracheal obstruction in a patient with coeliac disease.

Thorax ◽  
1989 ◽  
Vol 44 (6) ◽  
pp. 519-520 ◽  
Author(s):  
D J Seddon ◽  
K F Chung ◽  
F J Paradinas ◽  
E S Newlands ◽  
P D Snashall
Keyword(s):  
T Cell ◽  
Coeliac Disease ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Tracheal Obstruction

scholarly journals Monomorphic epitheliotropic intestinal T-cell lymphoma presenting as melena with long-term survival: A case report and review of literature

2021 ◽  
Vol 27 (38) ◽  
pp. 6501-6510
Author(s):  
Sotaro Ozaka ◽  
Kunimitsu Inoue ◽  
Tomoya Okajima ◽  
Takako Tasaki ◽  
Shimpei Ariki ◽  
...  
Keyword(s):  
Case Report ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Review Of Literature ◽  
Term Survival ◽  
Long Term Survival

Long-term survival in two patients with hepatosplenic T cell lymphoma treated with interferon-alpha

2008 ◽  
Vol 49 (7) ◽  
pp. 1420-1423 ◽  
Author(s):  
Michael Robert Humphreys ◽  
Maria Cino ◽  
Ian Quirt ◽  
David Barth ◽  
Vishal Kukreti
Keyword(s):  
T Cell ◽  
Interferon Alpha ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Term Survival ◽  
Long Term Survival ◽  
Hepatosplenic T Cell Lymphoma

Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma

Chemotherapy ◽  
2016 ◽  
Vol 62 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Harumi Kato ◽  
Kazuhito Yamamoto ◽  
Yusuke Higuchi ◽  
Hideyuki Yamamoto ◽  
Toko Saito ◽  
...  
Keyword(s):  
Elderly Patient ◽  
T Cell ◽  
Antitumor Immunity ◽  
Clinical Case ◽  
Cell Lymphoma ◽  
The Elderly ◽  
Salvage Chemotherapy ◽  
T Cell Lymphoma ◽  
Toxicity Profile ◽  
Angioimmunoblastic T Cell Lymphoma

There are few effective options for salvage therapy in elderly patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). The anti-CCR4 antibody mogamulizumab works via antibody-dependent cytotoxic activity, reduces regulatory T cells, and evokes antitumor immunity in cancer patients. We report a 78-year-old patient with refractory AITL receiving a new immunochemotherapy consisting of sequential mogamulizumab administration followed by the GDP (gemcitabine, dexamethasone and cisplatin) regimen. A favorable consolidative effect of the GDP regimen could be observed in the patient who had partial remission after administration of mogamulizumab monotherapy. The regimen showed an acceptable toxicity profile without serious autoimmunity and an expected treatment response for the elderly patient with primary refractory AITL. This clinical case is the first report of salvage chemotherapy including mogamulizumab for primary refractory AITL described in the literature.

Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients

1999 ◽  
Vol 40 (3) ◽  
pp. 418-425 ◽  
Author(s):  
Herschel S. Zackheim ◽  
Smita Amin ◽  
Mohammed Kashani-Sabet ◽  
Alex McMillan
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document